BCL2L1 and acute myeloid leukemia: Previous studies showed an improvement of efficacy of VEN in combination with drugs that downregulated MCL1 and/or BCL-XL, such as HMAs and cytarabine which exert a synergistic effect with VEN to interfere with the energy metabolism and kill AML tumor cells [20,22,23,51,52,53,54,55,56,57].